Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Wegovy received UK marketing authorisation in 2023, and NICE guidance (TA875) supports its use within the NHS for adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities), when provided through specialist weight management services, and for a maximum duration of 2 years
Focus on what you can control
Design-related topics that were discussed in the literature in early 2000s such as frequency of alarms or reminders, window of availability stopped being explored and consequently, new empirical evidence is missing
An 18-year follow-up
[8] Patients and clinicians should work collaboratively to reassess treatment plans, particularly in the early weeks of retatrutide use when appetite changes and weight loss are most pronounced
doi:10.1136/bmjdrc-2020-001856 Horikawa C, Aida R, Kamada C, et al
US$ 27.00
US$ 20.07
US$ 26.43
US$ 29.62
